Osteoporosis is the most common chronic metabolic bone disease characterized by decreased bone mass per unit volume, decreased bone strength, and easier fracture in the affected bone. It is estimated that more than 200 million men and women worldwide suffer from osteoporosis. Given the rapid development of the global population ageing, osteoporosis may become a global challenge affecting human health and quality of life. The regulation of bone mass, or bone remodeling, in adults is a dynamic process orchestrated by osteoblasts and osteoclasts. Bones are continuously resorbed by osteoclasts and replaced with new bones formed by osteoblasts. The structural integrity and mechanical property of bony tissue rely on coupled bone remodeling. The balance between bone resorption and bone formation and the regulation of this process play an important role in maintaining bone density and mineral homeostasis under a healthy condition. Recent studies on the basic molecular mechanisms and clinical significance of osteoporosis have identified new therapeutic targets. Emerging therapies targeting entirely new disease mechanisms may provide powerful approaches for osteoporosis treatment in the future. For example, TNF receptor-associated factor 3 (TRAF3), a member of the tumor necrosis factor receptor–associated factor (TRAF) family, was closely related to bone metabolism, which may be involved in osteoporosis as an important signalling molecule. Chronic intermittent hypobaric hypoxia (CIHH) has beneficial effects on the body and tissue including increasing bone density and improving osteoporosis by adaptive mechanism stimulated by intermittent and moderate hypoxia simulating high altitude. Therefore, CIHH may be a non-pharmacological means for the treatment of osteoporosis. It is now more important than ever before to understand the novel mechanisms of osteoporosis and provide appropriate strategies for prevention and treatment.
This Research Topic aims at determining osteoporosis caused by different conditions in disease or normal aging and finding the respective countermeasures for different situations. In addition to the existing conventional treatments, other effective strategies are badly needed to treat osteoporosis.
We welcome the submission of Original Research papers and Review articles including but not limited to basic research, clinical research, development and application of translational medicine, concise reviews, systemic reviews, meta-analyses, commentaries and viewpoints, on the following themes:
• New understanding of osteoporosis
• Specific treatment of osteoporosis
• Molecular mechanisms involved in bone remodeling
• Immunoregulation of bone remodeling
• The effects of senescence-associated secretory phenotype (SASP) on skeletal aging
Osteoporosis is the most common chronic metabolic bone disease characterized by decreased bone mass per unit volume, decreased bone strength, and easier fracture in the affected bone. It is estimated that more than 200 million men and women worldwide suffer from osteoporosis. Given the rapid development of the global population ageing, osteoporosis may become a global challenge affecting human health and quality of life. The regulation of bone mass, or bone remodeling, in adults is a dynamic process orchestrated by osteoblasts and osteoclasts. Bones are continuously resorbed by osteoclasts and replaced with new bones formed by osteoblasts. The structural integrity and mechanical property of bony tissue rely on coupled bone remodeling. The balance between bone resorption and bone formation and the regulation of this process play an important role in maintaining bone density and mineral homeostasis under a healthy condition. Recent studies on the basic molecular mechanisms and clinical significance of osteoporosis have identified new therapeutic targets. Emerging therapies targeting entirely new disease mechanisms may provide powerful approaches for osteoporosis treatment in the future. For example, TNF receptor-associated factor 3 (TRAF3), a member of the tumor necrosis factor receptor–associated factor (TRAF) family, was closely related to bone metabolism, which may be involved in osteoporosis as an important signalling molecule. Chronic intermittent hypobaric hypoxia (CIHH) has beneficial effects on the body and tissue including increasing bone density and improving osteoporosis by adaptive mechanism stimulated by intermittent and moderate hypoxia simulating high altitude. Therefore, CIHH may be a non-pharmacological means for the treatment of osteoporosis. It is now more important than ever before to understand the novel mechanisms of osteoporosis and provide appropriate strategies for prevention and treatment.
This Research Topic aims at determining osteoporosis caused by different conditions in disease or normal aging and finding the respective countermeasures for different situations. In addition to the existing conventional treatments, other effective strategies are badly needed to treat osteoporosis.
We welcome the submission of Original Research papers and Review articles including but not limited to basic research, clinical research, development and application of translational medicine, concise reviews, systemic reviews, meta-analyses, commentaries and viewpoints, on the following themes:
• New understanding of osteoporosis
• Specific treatment of osteoporosis
• Molecular mechanisms involved in bone remodeling
• Immunoregulation of bone remodeling
• The effects of senescence-associated secretory phenotype (SASP) on skeletal aging
